Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $34.94 which represents a slight increase of $0.89 or 2.61% from the prior close of $34.05. The stock opened at $33.85 and ...

Viking has long been viewed as a takeover target, given the positive data from early VK2735 trials. The company’s most recent ...

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $32.87 which represents a slight increase of $0.22 or 0.67% from the prior close of $32.65. The stock opened at $32.87 and ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Viking Therapeutics (NASDAQ:VKTX – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at ...

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the thirteen brokerages that are presently covering the stock, MarketBeat ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...